ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.

Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology ...

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Icon (ICLR – Research Report). The company’s ...

Revenue: US$863.0k (down 8.1% from 3Q 2023). Net loss: US$876.0k (down from US$64.0k profit in 3Q 2023). US$0.69 loss per share (down from US$0.32 profit in 3Q 2023). Looking ahead, revenue is ...

Icon Energy (ICON) announced the pricing of its public offering of 9,160,305 units at a public offering price of $1.31 per unit. Each unit ...

Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, "ICON continues to navigate dynamic clinical development ...